Ireland - English - HPRA (Health Products Regulatory Authority)

norbrook laboratories (ireland) limited - procaine benzylpenicillin - suspension for injection - 300 milligram(s)/millilitre - benzylpenicillin

Ireland - English - HPRA (Health Products Regulatory Authority)

norbrook laboratories (ireland) limited - procaine benzylpenicillin - suspension for injection - 300 milligram(s)/millilitre - procaine benzylpenicillin

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - oxcarbazepine, quantity: 60 mg/ml - oral liquid, suspension - excipient ingredients: saccharin sodium; propylene glycol; purified water; methyl hydroxybenzoate; sorbitol solution (70 per cent) (non-crystallising); peg-8 stearate; sorbic acid; propyl hydroxybenzoate; ascorbic acid; dispersible cellulose; fragrance (perfume) - for use as monotherapy or adjunctive therapy for the treatment of partial seizures and generalised tonic-clonic seizures, in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - amoxicillin trihydrate, quantity: 57.4 mg/ml (equivalent: amoxicillin, qty 50 mg/ml) - suspension, powder for - excipient ingredients: sorbitol; sodium benzoate; saccharin sodium; disodium edetate; xanthan gum; silicon dioxide; flavour - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms:,note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxicillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results.,skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e.coli,respiratory (acute and chronic): h.influenzae, streptococcus; s.pneumoniae; staphylococcus, non-penicillinase-producing; e.coli,genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli, p.mirabilis and s.faecalis.,gonorrhoea: n.gonorrhoeae (non-penicillinase producing).,prophylaxis of endocarditis: [trade name] may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - amoxicillin trihydrate, quantity: 28.7 mg/ml (equivalent: amoxicillin, qty 25 mg/ml) - suspension, powder for - excipient ingredients: sorbitol; sodium benzoate; saccharin sodium; disodium edetate; xanthan gum; silicon dioxide; flavour - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms:,note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxicillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results.,skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e.coli,respiratory (acute and chronic): h.influenzae, streptococcus; s.pneumoniae; staphylococcus, non-penicillinase-producing; e.coli,genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli, p.mirabilis and s.faecalis.,gonorrhoea: n.gonorrhoeae (non-penicillinase producing).,prophylaxis of endocarditis: [trade name] may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - amoxicillin trihydrate, quantity: 57.4 mg/ml (equivalent: amoxicillin, qty 50 mg/ml) - suspension, powder for - excipient ingredients: sorbitol; sodium benzoate; saccharin sodium; disodium edetate; xanthan gum; silicon dioxide; flavour - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms:,note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxicillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results.,skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e.coli,respiratory (acute and chronic): h.influenzae, streptococcus; s.pneumoniae; staphylococcus, non-penicillinase-producing; e.coli,genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli, p.mirabilis and s.faecalis.,gonorrhoea: n.gonorrhoeae (non-penicillinase producing).,prophylaxis of endocarditis: [trade name] may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - amoxicillin trihydrate, quantity: 28.7 mg/ml (equivalent: amoxicillin, qty 25 mg/ml) - suspension, powder for - excipient ingredients: sorbitol; sodium benzoate; saccharin sodium; disodium edetate; xanthan gum; silicon dioxide; flavour - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms:,note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxicillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results.,skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e.coli,respiratory (acute and chronic): h.influenzae, streptococcus; s.pneumoniae; staphylococcus, non-penicillinase-producing; e.coli,genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli, p.mirabilis and s.faecalis.,gonorrhoea: n.gonorrhoeae (non-penicillinase producing).,prophylaxis of endocarditis: [trade name] may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - amoxicillin trihydrate, quantity: 57.4 mg/ml (equivalent: amoxicillin, qty 50 mg/ml) - suspension, powder for - excipient ingredients: sorbitol; sodium benzoate; saccharin sodium; disodium edetate; xanthan gum; silicon dioxide; flavour - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms:,note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxicillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results.,skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e.coli,respiratory (acute and chronic): h.influenzae, streptococcus; s.pneumoniae; staphylococcus, non-penicillinase-producing; e.coli,genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli, p.mirabilis and s.faecalis.,gonorrhoea: n.gonorrhoeae (non-penicillinase producing).,prophylaxis of endocarditis: [trade name] may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - amoxicillin trihydrate, quantity: 28.7 mg/ml (equivalent: amoxicillin, qty 25 mg/ml) - suspension, powder for - excipient ingredients: sorbitol; sodium benzoate; saccharin sodium; disodium edetate; xanthan gum; silicon dioxide; flavour - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms:,note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxicillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results.,skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e.coli,respiratory (acute and chronic): h.influenzae, streptococcus; s.pneumoniae; staphylococcus, non-penicillinase-producing; e.coli,genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli, p.mirabilis and s.faecalis.,gonorrhoea: n.gonorrhoeae (non-penicillinase producing).,prophylaxis of endocarditis: [trade name] may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - English - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - nitisinone, quantity: 4 mg - oral liquid, suspension - excipient ingredients: hypromellose; glycerol; polysorbate 80; sodium benzoate; citric acid monohydrate; sodium citrate; purified water; flavour - orfadin (nitisinone) is indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.